If you love a quick profit and take a few risks in the stock market and stock trading you choose shares, medicine, real estate, derived in order to buy and win exciting of dollars quickly
Below is a list of the best selections drug stocks in 2011. These Home 2011 drug stocks are my favorite to buy securities and some stocks that will trade personally. Several biotechnology stocks have already made quite a stir in 2011 and we will show below. Stocks of medicines are still hot in 2011 and could even surpass the U.S. markets. Two of the best biotech stocks in 2011 are genetic Technologies Ltd. (GEN) and Amarin Corporation plc (AMRN).
Top Drug Stocks 2011 - Stocks to Buy - Drug Stocks - Genetic Technologies Ltd. (GENE) - The top drug stock in 2011 so far is Genetic Technologies Ltd. (GENE). GENE stock hit a 52 week high at $9.60 in May 2011 and is up 626% in the past six months. Genetic Technologies Limited engages in the provision of genetic testing and canine reproductive services primarily in Australia. The company offers genetic testing services on humans and animals, which include human diagnostics, forensics, and animal pedigree tests. It also involves in licensing its non-coding DNA patents; and the research and development in the fields of genetics and related areas. In addition, the company provides BREVAGen, a diagnostic test for breast cancer.
The latest news on their Breast Cancer test has the stock ripping higher. Genetic Technologies Secures US Approval for Launch of BREVAGen Breast Cancer Risk Test - Genetic Technologies - first Australian CLIA approved laboratory - Runway clear for BREVAGen US launch, large addressable market with no direct competitors - GTG's Melbourne laboratory now one of only a few laboratories in the world with CLIA, NATA, ISO & RCPA accreditation/certification
GENE could soar above $10 in 2011 given the momentum. Although risky, GENE is now the top biotech stock to watch in 2011.
#2 Top Drug Stock to Watch 2011 - Drug Stocks - Amarin Corporation plc (AMRN) - My 2nd drug stock pick in 2011 is Amarin Corporation plc (AMRN). Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. The company's lead product candidate includes AMR101, a prescription grade Omega-3 product, which is in a second Phase III clinical trials for the treatment of patients on statin therapy with high triglycerides and mixed dyslipidemia. It also has next-generation lipid candidates under evaluation for preclinical development. AMRN stock has been hot in 2011 and is up 423% in the past six months. Recently, Amarin soared due to the following news: Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
- Triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively
- LDL-C decreased at both doses within the predefined non-inferiority boundary with a statistically significant 6.2% decrease in LDL-C from baseline versus placebo at 4 gram dose
- All results were incremental to background statin therapy
- Safety profile similar to placebo and similar to MARINE trial results
- Results position AMR101 to be first-in-class product for treatment of high triglycerides
The latest news on their Breast Cancer test has the stock ripping higher. Genetic Technologies Secures US Approval for Launch of BREVAGen Breast Cancer Risk Test - Genetic Technologies - first Australian CLIA approved laboratory - Runway clear for BREVAGen US launch, large addressable market with no direct competitors - GTG's Melbourne laboratory now one of only a few laboratories in the world with CLIA, NATA, ISO & RCPA accreditation/certification
GENE could soar above $10 in 2011 given the momentum. Although risky, GENE is now the top biotech stock to watch in 2011.
#2 Top Drug Stock to Watch 2011 - Drug Stocks - Amarin Corporation plc (AMRN) - My 2nd drug stock pick in 2011 is Amarin Corporation plc (AMRN). Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. The company's lead product candidate includes AMR101, a prescription grade Omega-3 product, which is in a second Phase III clinical trials for the treatment of patients on statin therapy with high triglycerides and mixed dyslipidemia. It also has next-generation lipid candidates under evaluation for preclinical development. AMRN stock has been hot in 2011 and is up 423% in the past six months. Recently, Amarin soared due to the following news: Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
- Triglyceride levels decreased 21.5% and 10.1% from baseline versus placebo at 4 gram and 2 gram doses, respectively
- LDL-C decreased at both doses within the predefined non-inferiority boundary with a statistically significant 6.2% decrease in LDL-C from baseline versus placebo at 4 gram dose
- All results were incremental to background statin therapy
- Safety profile similar to placebo and similar to MARINE trial results
- Results position AMR101 to be first-in-class product for treatment of high triglycerides
Now is the time to be investing in gold online. Gold will rise this year 3x the rate as past years.:)
ReplyDelete